New Oral Medication Shows Efficacy for Type 2 Diabetes and Weight Loss

A recent phase 2b clinical trial demonstrated promising outcomes for elecoglipron, an oral GLP-1 receptor agonist, in treating type 2 diabetes. The study indicated significant improvements in blood sugar control and notable weight reduction among participants. These findings suggest a potential new therapeutic option for managing the condition.